Prescription drug · NDA
Foundayo (orforglipron) NDC 0002-4794
Orforglipron calcium 5.5 mg/1 · Tablet, Film coated · Oral · Eli Lilly and Company
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0002-4794-31 | 00002479431 | 1 BOTTLE in 1 CARTON (0002-4794-31) / 30 TABLET, FILM COATED in 1 BOTTLE (0002-4794-01)Marketed from Apr 1, 2026 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Foundayo
- Generic name (nonproprietary)
- orforglipron
- Active ingredients
- Orforglipron calcium — 5.5 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Eli Lilly and Company
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 220934
- Marketing start
- Listing expires
- Other FDA classes
- Decreased Gastric Motility (Physiologic effect)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)Increased Gastric Muscle Tone (Physiologic effect)
- Identifiers
- Product ID 0002-4794_ebe44919-a00d-4ea1-a511-18e6a87da34cSPL ID ebe44919-a00d-4ea1-a511-18e6a87da34cSPL set ID 8ac446c5-feba-474f-a103-23facb9b5c62RxCUI 2739844, 2739850, 2739852, 2739854, 2739856, 2739858, 2739860, 2739862, 2739864, 2739866, 2739868, 2739870UNII VI5M9OZV2X
- Pharmacologic class
- GLP-1 Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400002479431followed by a unit qualifier and the quantityPackage 00002-4794-31. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. FOUNDAYO™ is a GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. ( 1 ) Limitations of Use Concomitant use with another GLP-1 receptor agonist is not recommended. ( 1 ) Limi…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 220934
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Foundayoorforglipron | Orforglipron calcium 2.5 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4503 |
| Foundayoorforglipron | Orforglipron calcium 14.5 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4839 |
| Foundayoorforglipron | Orforglipron calcium 9 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4803 |
| Foundayoorforglipron | Orforglipron calcium 17.2 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4953 |
| Foundayoorforglipron | Orforglipron calcium .8 mg/1 | Tablet, Film coatedOral | Eli Lilly and Company | 0002-4178 |